Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study
Minimally Invasive Micro Sclerostomy (MIMS®) Inferonasal Procedure: Long-Term Follow-Up Extension Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Khan Lau, OD
- Phone Number: 8082862666
- Email: khan@sanoculis.com
Study Locations
-
-
-
Yerevan, Armenia
- Recruiting
- S. Malayan Eye Center
-
Contact:
- Lilit A Voskanyan, MD
- Phone Number: +374-10-34-49-44
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
1. Subject who underwent MIMS® inferonasal procedure, and surgery was performed not earlier than 24 months from enrollment
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Inferonasal MIMS Surgery Cohort
Cohort that includes subjects that have undergone the MIMS® inferonasal surgery.
|
The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intraocular Pressure Change (Baseline to 24 months)
Time Frame: Baseline to 24 months post-MIMS® surgery
|
Change in IOP from medicated baseline to 24 months post-MIMS® surgery
|
Baseline to 24 months post-MIMS® surgery
|
|
Intraocular Pressure Change (Baseline to 30 months)
Time Frame: Baseline to 30 months post-MIMS® surgery
|
Change in IOP from medicated baseline to 30 months post-MIMS® surgery
|
Baseline to 30 months post-MIMS® surgery
|
|
Change in Number of Topical Intraocular Pressure Lowering Medications (Baseline to 24 Months)
Time Frame: Medicated baseline to 24 months post-MIMS® surgery
|
Change in the number of topical IOP-lowering medications from medicated baseline to 24 months post-MIMS® surgery
|
Medicated baseline to 24 months post-MIMS® surgery
|
|
Change in Number of Topical Intraocular Pressure Lowering Medications (Baseline to 30 Months)
Time Frame: Medicated baseline to 30 months post-MIMS® surgery
|
Change in the number of topical IOP-lowering medications from medicated baseline to 30 months post-MIMS® surgery
|
Medicated baseline to 30 months post-MIMS® surgery
|
|
Surgery Success Rate (24 months)
Time Frame: 24 months post-MIMS® surgery
|
Success rate 24 months post-MIMS® surgery
|
24 months post-MIMS® surgery
|
|
Surgery Success Rate (30 months)
Time Frame: 30 months post-MIMS® surgery
|
Success rate 30 months post-MIMS® surgery
|
30 months post-MIMS® surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative Complication Safety Outcomes
Time Frame: Baseline to 30 months post-MIMS® surgery
|
Late (greater than 12 months) postoperative complications
|
Baseline to 30 months post-MIMS® surgery
|
|
Interventional Safety Outcomes
Time Frame: Baseline to 30 months post-MIMS® surgery
|
Late (greater than 12 months) postoperative interventions
|
Baseline to 30 months post-MIMS® surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MMS-EEU-8
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.